Brigit Biofarmaka Teknologi Tbk PT

The company maintains a strong liquidity position with a current ratio of 6.65 and a price-to-book ratio of 1.78, indicating a relatively low debt burden and a market valuation that reflects its tangible assets. Its liquidity is further supported by a cash and equivalents balance of 29.3 billion IDR, which is substantial relative to its total liabilities of 24.1 billion IDR. Profitability metrics show a return on equity of 21.18% and a return on assets of 17.28%, both of which exceed the typical thresholds for the pharmaceutical industry, suggesting efficient use of equity and assets. The company's operating income of 33.1 billion IDR and net income of 22.6 billion IDR reflect strong operational performance. The company's revenue is derived from a diverse set of segments, including herbal capsules, cosmetics, and powdered drinks, with no single segment dominating the revenue mix. This diversification helps mitigate the risk of over-reliance on any one product line. Geographically, the company is primarily focused on the Indonesian market, with no significant international revenue disclosed. The company's growth trajectory is positive, with a revenue of 160.1 billion IDR in the latest period. While no specific growth rate is provided, the company's strong profitability and liquidity suggest a stable and potentially growing business. The company's capital expenditure of -20.6 billion IDR indicates a significant investment in infrastructure or expansion. Risk factors are minimal, with low liquidity and dilution risks identified. The company has no immediate filing-based liquidity or dilution flags, and the debt-to-equity ratio of 0.07 suggests a conservative capital structure. The absence of dilution potential and the low risk of equity dilution further support the company's financial stability. Recent events and filings do not indicate any significant changes in the company's operations or financial status. The company continues to operate under its existing business model, with no major disruptions or strategic shifts reported.